Method of treatment

Patent metadata

Field	Value
Publication number	US-2016200808-A1
Application number	US-201414916141-A
Country	US
Kind code	A1
Filing date	Sep 2, 2014
Priority date	Sep 2, 2013
Publication date	Jul 14, 2016
Grant date	—

Abstract

A protocol for pain management includes a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol includes the use of a CCL17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions. The CCL17 signaling antagonist includes an antibody or antigen-binding derivative thereof which binds to CCL17 or its receptor.

First claim

1 . A method for inducing an analgesic response to pain in a subject, said method comprising administering to said subject of an amount of a CCL17 signaling antagonist effective in reducing the level of or otherwise ameliorating the sensation of pain.

2 . The method of claim 1 further comprising administering another analgesic compound.

3 . The method of claim 2 wherein the other analgesic compound is selected from the group consisting of an NSAID, steroid, an anti-inflammatory cytokine, an N-type calcium channel antagonist, an antibody to an inflammatory cytokine, a neuronal excitation inhibitor, a narcotic, an anticonvulsant and a local anesthetic.

4 . The method of claim 1 , wherein the pain is neuropathic pain.

5 . The method of claim 1 , wherein the pain is inflammatory pain.

6 . The method of claim 5 , wherein, the inflammatory pain is associated with a condition selected from the group consisting of osteo-arthritis, rheumatoid arthritis, psoriatic arthropathy, arthritis associated with other inflammatory and autoimmune conditions, degenerative conditions, back strain, mechanical back pain, disc disease, post operative pain, pain from an injury, a soft tissue bruise, a strained ligament, a broken bone, an abscess, cellulitis, fibrositis, myositis, Felty's syndrome, Sjogren's syndrome, peripheral neuropathy, biorythmus, bunions, burstis of the knee, Celiac's disease, Cushing syndrome, Costochondritis, Teize's syndrome, dry eyes, ganglion, juvenile idiopathic arthritis (juvenile rheumatoid arthritis), scleritis, relapsing polychondritis, pleurisy, connective tissue disease, steroid drug withdrawal, amyloidosis, uveitis, Raynard's phenomenon, osteopenia, chronic pain, Still's disease, swollen lymph nodes, Lyme disease, gout, sacroliac joint dysfunction, knee pain, lupus and ankle pain.

7 . The method of claim 6 wherein the inflammatory pain is associated with osteoarthritis.

8 . The method of claim 5 wherein the inflammatory pain is associated with a condition selected from the group consisting of acne, angina, arthritis, aspiration pneumonia, disease, empyema, gastroenteritis, inflammation, intestinal flu, NEC, necrotizing enterocolitis, pelvic inflammatory disease (PID), pharyngitis, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyneuropathy and chronic inflammatory demyelinating polyradiculoneuropathy.

9 . The method of claim 1 wherein the CCL17 signaling antagonist is;
an antibody to CCL17 or CCL17 receptor or an antigen-binding fragment thereof, or a soluble CCL17 receptor or a CLL17 binding fragment thereof; or
a soluble CCL17 receptor, a CCL17 or its receptor expression inhibitor, an inhibitor of CCL17 or its receptor or is a degrading agent for CCL17 or its receptor.

10 . (canceled)

11 . The method of claim 9 , wherein the CCL17 receptor is CCR4 or other receptor.

12 . The method of claim 1 wherein the CCL17 signaling antagonist is administered in an amount of about 0.5 μg to about 20 mg per kg of body weight.

13 . The method of claim 1 wherein the subject is a human.

14 . A delivery system for inducing an analgesic response in a subject having paid, said delivery system comprising combined or separate formulations of (1) a CCL17 signaling antagonist; (2) optionally another analgesic compound; and optionally (3) one or more further active agents,

15 . A method of treating pain associated with a disease or physiological condition in a subject, said method comprising administering to said subject an effective amount of a CCL17 signaling antagonist.

16 . The method of claim 15 wherein the CCL17 signaling antagonist is a CCL17-specific antibody or CCL17 receptor-specific antibody or an antigen-binding fragment thereof or a soluble CCL17 receptor or a CCL17-binding fragment thereof.

17 . The method of claim 15 wherein the CCL17 signaling antagonist is a soluble CCL17 receptor, a CCL17 or its receptor expression inhibitor, an inhibitor of CCL17 or its receptor or is a degrading agent for CCL17 or its receptor.

18 . A method of treatment of a subject said method comprising selecting a subject on the basis of symptoms of pain and administering to said subject a CCL17 signaling antagonist.

19 . The method of claim 15 wherein the pain is neuropathic pain.

20 . The method of claim 15 wherein the pain is inflammatory pain.

21 . The method of claim 20 wherein the inflammatory pain is associated with a condition selected from the group consisting of osteo-arthritis, rheumatoid arthritis, psoriatic arthropathy, arthritis associated with other inflammatory and autoimmune conditions, degenerative conditions, back strain, mechanical back pain, disc disease, post operative pain, pain from an injury, a soft tissue bruise, a strained ligament, a broken bone, an abscess, cellulitis, fibrositis, myositis, Felty's syndrome, Sjogren's syndrome, peripheral neuropathy, biorythmus, bunions, burstis of the knee, Celiac's disease. Cushing syndrome, Costochondritis and Teize's syndrome, dry eyes, ganglion, juvenile idiopathic arthritis (juvenile rheumatoid arthritis), scleritis, relapsing polychondritis, pleurisy, connective tissue disease, steroid drug withdrawal, amyloidosis, uveitis, Raynard's phenomenon, osteopenia, chronic pain, Still's disease, swollen lymph nodes, Lyme disease, gout, sacroliac joint dysfunction, knee pain, lupus and ankle pain.

22 . The method of claim 20 wherein the inflammatory pain is associated with osteoarthritis.

23 . The method of claim 20 wherein the inflammatory pain is selected from the group consisting of acne, angina, arthritis, aspiration pneumonia, disease, empyema, gastroenteritis, inflammation, intestinal flu, NEC, necrotizing enterocolitis, pelvic inflammatory disease (PID), pharyngitis, pleurisy, raw throat, redness, rubor, sore throat, stomach flu and urinary tract infections, chronic inflammatory demyelinating polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyneuropathy and chronic inflammatory demyelinating polyradiculoneuropathy.

24 . The method of claim 15 wherein the subject is a human.

25 . The method of claim 15 wherein the CCL17 signaling antagonist is an antibody to CCL17 or CCL17 receptor or an antigen-binding fragment thereof or a CCL17 receptor or a CCL17-bindmg fragment thereof.

26 . The method of claim 15 wherein the CCL17 signaling antagonist is a soluble CCL17 receptor, a CCL17 or its receptor expression inhibitor, an inhibitor, of CCL17 or its receptor or is a degrading agent for CCL17 or its receptor.

27 .- 33 . (canceled)

Assignees

• Univ Melbourne

Inventors

• Cook Andrew
• Hamilton John
• Achuthan Adrian
• Lacey Derek

Classifications

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title